GLPG5201
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 1/2Wind-Down (Status Uncertain)
Key Facts
Indication
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Phase
Phase 1/2
Status
Wind-Down (Status Uncertain)
Company
About Galapagos
Galapagos is a commercial-stage biotech transitioning from a platform-centric discovery model to a lean, externally-focused business development engine. Its legacy is anchored by the successful JAK1 inhibitor filgotinib (Jyseleca), developed with Gilead, which provides European revenue and royalties. The company's current strategy, under new leadership, involves winding down internal cell therapy to redeploy capital towards acquiring late-stage clinical assets in high-value therapeutic areas like oncology and immunology, as exemplified by its new T cell engager collaboration with Gilead.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Drugs
| Drug | Company | Phase |
|---|---|---|
| Bexobrutideg (NX-5948) | Nurix Therapeutics | Phase 2 |